Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1808 | Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets Wiki | 1.00 |
| drug2168 | Lopinavir/ Ritonavir Oral Tablet Wiki | 1.00 |
| drug1807 | Hydroxychloroquine Sulfate Tablets Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012141 | Respiratory Tract Infections NIH | 0.16 |
| D014777 | Virus Diseases NIH | 0.11 |
| D003141 | Communicable Diseases NIH | 0.07 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0011947 | Respiratory tract infection HPO | 0.16 |
Navigate: Correlations HPO
There is one clinical trial.
RT-CoV-2 is a Phase I, open-label, dose escalation multicenter clinical trial to assess safety and immunogenicity of the candidate Coronavirus disease (COVID-19) vaccine GRAd-COV2 in Italian healthy volunteers aged 18-55 years and 65-85 years inclusive. GRAd-COV2 is based on a novel replication defective Gorilla Adenovirus and encodes for SARS-COV-2 Spike protein.
Description: Occurrence of solicited local AE signs and symptoms
Measure: Assess the safety, tolerability and reactogenicity of GRAd-COV2: Occurrence of solicited local AE signs and symptoms Time: 7 days following the vaccinationDescription: Occurrence of solicited systemic AE signs and symptoms
Measure: Assess the safety, tolerability and reactogenicity of GRAd-COV2: Occurrence of solicited systemic AE signs and symptoms Time: 7 days following the vaccinationDescription: Occurrence of unsolicited AE
Measure: Assess the safety, tolerability and reactogenicity of GRAd-COV2: Occurrence of unsolicited AE Time: 28 days following the vaccinationDescription: Change from baseline for safety laboratory measures
Measure: Assess the safety of GRAd-COV2 by laboratory measures: full blood count; blood Biochemistry (Sodium, Potassium, Albumin, Liver Function Tests; Renal function, lactate dehydrogenases (LDH), alkaline phosphatases (ALP)). Time: 24 weeks following the vaccinationDescription: Occurrence of serious AE
Measure: Assess the safety, tolerability and reactogenicity of GRAd-COV2: Occurrence of serious AE Time: 24 weeks following the vaccinationDescription: To assess the cellular and humoral immune response to SARS-CoV2 elicited by the vaccine
Measure: Immunogenicity Time: week 1, 2, 4, 8, 12 and 24Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports